The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar
Novo Nordisk has said it will temporarily reduce production of the lower starting doses of its weight-loss drug Wegovy, as demand for the therapy continues to challenge it
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg
Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t
Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.
Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera